gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CDNAHealthcareMedical Labs

CareDx, Inc. (CDNA)

$85.86−2.95%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$85.86▲ 491.32% in range
Nov 4, 2025Low $14.52 · High $88.47Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

CareDx closed at $85.86 on Nov 4, down 2.95%, 3.0% below its 52-week closing high. Volume of 1.5M shares was 1.03× its 20-day average (close to normal).

Split-adjusted performance: +34.6% over one month, +309.8% over six months, +481.3% over one year.

In the quarter ended Sep 30, 2026, revenue was $139.36M, up 39.3% from a year earlier, with a net margin of 13.8%.

Short interest was 6.7M shares at the Oct 15 settlement, up 1.9% from the prior report (13.4% of float, 4.5 days to cover).

Market cap$4.51B52.5M shares
Revenue · quarter$139.4M+39.3% YoY
Diluted EPS$0.35+1066.7% YoY
P/E · TTM35.1×P/S 9.1×
Net margin13.8%Gross 71.1%
Dividend yieldNone
52-week range14.52 – 88.47−3.0% from high
Volume1.5M1.03× 20-day avg
Volatility · 60d62.4%Annualised
Short % of float13.4%4.5 days to cover
Net cash$250.5MCash $250.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +19.0%1M +34.6%3M +91.6%6M +309.8%YTD +355.7%1Y +481.3%3Y +1567.2%5Y +27.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum100
Revenue growth83
Net margin91
Value (low P/E)—
Size65

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short6.7M+1.9% vs prior
Days to cover4.5Settled Oct 15
% of float13.4%
Short vol. 10d52.3%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CDNACareDx$85.86−2.95%+309.8%+39.3%13.8%35.1$4.51B
VCYTVeracyte$52.52+4.43%+27.5%+15.5%17.0%36.9$4.22BCompare
BLLNBillionToOne$113.89+3.11%+39.9%—7.4%—$5.37BCompare
CELCCelcuity$69.24−0.69%−50.3%———$3.39BCompare
RDNTRadNet$80.26+9.67%+36.9%+25.0%1.2%—$6.32BCompare
GRALGRAIL$143.66+3.03%+128.9%+25.7%−246.7%—$6.42BCompare
CAICaris Life Sciences$33.22+1.13%+73.7%+45.4%−0.2%89.3$9.39BCompare
FTREFortrea Holdings$20.83−0.57%+33.2%−1.4%0.1%—$2.01BCompare
PSNLPersonalis$15.79+0.25%+160.1%+30.0%−141.7%—$1.69BCompare

News about CareDx

All news →
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing GrowthZacks Investment Research · 1d ago▲ PositiveWhy CareDx Stock Soared TodayThe Motley Fool · 5d ago▲ PositiveCareDx (CDNA) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research · 6d ago▲ PositiveCareDx to Report Q3 Earnings: Transplant Testing Growth in FocusZacks Investment Research · Oct 26, 2026NeutralWhy CareDx Stock Jumped TodayThe Motley Fool · Jul 31, 2026▲ Positive

Quick answers

What does CareDx do?
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients.
What is CDNA's market cap?
$4.51B, based on the Nov 4 close of $85.86.
What is CDNA's P/E ratio?
35.1× trailing-twelve-month earnings of $128.63M.
Does CareDx pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CDNA is sold short?
6.7M shares, 13.4% of float, as of Oct 15, 2026.
What sector is CDNA in?
Healthcare, in the Medical Labs industry.

About CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

HQ: Brisbane, CA765 employeesListed Jul 17, 2014caredx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology